Navigation Links
Targeted therapy decreases progression rate in thyroid cancer
Date:9/17/2010

ROCHESTER, Minn. -- The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Keith Bible describing the research, are available on the Mayo Clinic News Blog. Password: bible.

The researchers studied 37 patients with the most aggressive form of this cancer -- developing in less than 5 percent of patients with differentiated thyroid cancer -- and found that about half (18) patients had a long-lasting response to pazopanib. Of that group, 12 are still alive without disease progression. The median progression-free survival time was 11.7 months, with an overall survival rate of 81 percent at one year.

The researchers say that, to their knowledge, these findings represent by far the highest response rate yet reported in such aggressive cases of differentiated thyroid cancer. They caution however, that this drug is not meant to be used in slow-growing differentiated thyroid cancers and that they cannot assess the survival advantage pazopanib offers to the patients studied.

Determining survival benefit would require a randomized clinical trial testing the agent, which inhibits all three vascular endothelial growth factor (VEGF) receptors, compared to other treatments or a placebo.

"In this group of patients, we would have expected the cancer to have progressed in everyone within six mo
'/>"/>

Contact: Nicole Engler
engler.nicole@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted agent shows promise for chronic lymphoid leukemia
2. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
3. In Early Trial, Targeted Therapy Fights Advanced Melanoma
4. New targeted therapy for advanced melanoma associated with 80 percent response rate
5. Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene
6. NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer
7. Radiation device allows for targeted breast radiation to control cancer
8. Surveillance colonoscopy should be targeted to high-risk patients
9. Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
10. Experimental targeted therapy shows early promise against medulloblastomas
11. Targeted Therapy Shows Promise Against Deadly Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 ... contains 15 seconds of unique footage that users can shrink and stretch in the ... and more. Users can customize color, brightness, scale, speed, range, and flare attributes with ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health ... and sell Arterosil and Arterosil HP, and that all claims and counterclaims have ... Health Sciences, LLC (VHS) in the United States District Court for the Southern ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 ... Zoo to celebrate children helping children, a thank you to the many creative ... have contributed to the United Methodist initiative to end malaria deaths. , The ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, ... the “Music With A Mission” benefit concert in Mendon, IL. Held in the Show ... money to support music education programs in the underfunded local school districts of Mendon ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... July 12 Volunteers and staff of the,American Heart ... Michael E. DeBakey, who died yesterday at the age ... cardiovascular medicine and is,personally responsible for developing the field ... American Heart Association.,"He single-handedly started surgery of the aorta, ...
... Care for Military, Vets, All Americans, WASHINGTON, July ... joined with national leaders in offering,condolences to the family ... medical pioneer with long ties to the Department,of Veterans ... DeBakey,s skills as a surgeon and manager, along with ...
... meets with President Sirleaf while part of Mercy Ships Crew ... ... Recently returned from a week-long international humanitarian mission to support Mercy ... upcoming NFL training camp with an additional sense of purpose knowing ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... of venous reflux disease, announced,today the resignation of Kathleen ... served on VNUS, Board of Directors since April 1997 ... that funded the company during,its start-up activities. There are ...
... assessment tool, SNPs made no difference, study finds , , ... predicting one,s chances of developing breast cancer do not ... some genetic markers for the disease, a new report ... (SNPs) that indicate a small but statistically significant increase ...
... $850 million in cuts, WASHINGTON, July 11 ... important benefits and pay more out of,pocket for ... Medicare,Advantage plan altogether under legislation approved this week ... would cut nearly $14 billion from the,Medicare Advantage ...
Cached Medicine News:Health News:American Heart Association Saddened by Death of Surgical Pioneer Michael E. DeBakey 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 3Health News:VNUS Medical Technologies, Inc. Announces Board of Director Resignation 2Health News:Recent Genetic Discoveries Don't Improve Prediction of Breast Cancer 2Health News:Pennsylvania Seniors' Medicare Advantage Benefits at Risk 2
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... , August 28, 2015 The ... Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) ... The global market for Eubiotics was valued at USD 4.62 ... Billion by 2020, at a CAGR of 7.4% from 2015 ...
(Date:8/27/2015)... 2015  The Academy of Managed Care Pharmacy ... (FDA,s) draft guidance and proposed rule that calls ... bear a nonproprietary name with an FDA-designated suffix. ... decision from the FDA on the naming issue ... urging the agency to use the same nonproprietary ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Demonstrates Significant Reduction in Incidence of GI Ulcers and ... Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced ... trial evaluating the gastrointestinal (GI) safety of its investigational ... bio-activated prodrugs being developed for the chronic treatment of ...
... , HOUSTON, Oct. 27 Bellicum Pharmaceuticals, Inc. today announced ... new funds will be used to complete the company,s ongoing ... independent prostate cancer, and to prepare for Phase IIb trials. ... trial in mid 2010. , The new funding brings the ...
Cached Medicine Technology:Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study 2Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study 3Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study 4Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: